Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 24

1.

PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients.

Fourcade J, Kudela P, Sun Z, Shen H, Land SR, Lenzner D, Guillaume P, Luescher IF, Sander C, Ferrone S, Kirkwood JM, Zarour HM.

J Immunol. 2009 May 1;182(9):5240-9. doi: 10.4049/jimmunol.0803245.

2.

Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection.

Blackburn SD, Shin H, Haining WN, Zou T, Workman CJ, Polley A, Betts MR, Freeman GJ, Vignali DA, Wherry EJ.

Nat Immunol. 2009 Jan;10(1):29-37. doi: 10.1038/ni.1679. Epub 2008 Nov 30.

3.

Tumor-infiltrating T cells correlate with NY-ESO-1-specific autoantibodies in ovarian cancer.

Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger NJ, Ng A, Nielsen JS, Sahota R, Tran E, Webb JR, Wong MQ, Wick DA, Wray A, McMurtrie E, Köbel M, Kalloger SE, Gilks CB, Watson PH, Nelson BH.

PLoS One. 2008;3(10):e3409. doi: 10.1371/journal.pone.0003409. Epub 2008 Oct 15.

4.

Programmed death (PD)-1:PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis.

Jurado JO, Alvarez IB, Pasquinelli V, Martínez GJ, Quiroga MF, Abbate E, Musella RM, Chuluyan HE, García VE.

J Immunol. 2008 Jul 1;181(1):116-25.

5.

Inhibitory B7-family molecules in the tumour microenvironment.

Zou W, Chen L.

Nat Rev Immunol. 2008 Jun;8(6):467-77. doi: 10.1038/nri2326. Review.

PMID:
18500231
6.

Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes.

Demotte N, Stroobant V, Courtoy PJ, Van Der Smissen P, Colau D, Luescher IF, Hivroz C, Nicaise J, Squifflet JL, Mourad M, Godelaine D, Boon T, van der Bruggen P.

Immunity. 2008 Mar;28(3):414-24. doi: 10.1016/j.immuni.2008.01.011.

7.

Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer.

Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, Rodabaugh K, Lele S, Shrikant P, Old LJ, Gnjatic S.

Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12837-42. Epub 2007 Jul 25.

8.

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.

Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5. Epub 2007 Feb 21.

9.

Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer.

Coukos G, Conejo-Garcia JR, Buckanovich R, Benencia F.

Adv Exp Med Biol. 2007;590:185-93. Review. No abstract available.

PMID:
17191386
10.

Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression.

Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K, Wehbi M, Hanson HL, Steinberg JP, Masopust D, Wherry EJ, Altman JD, Rouse BT, Freeman GJ, Ahmed R, Grakoui A.

J Virol. 2007 Mar;81(6):2545-53. Epub 2006 Dec 20.

11.

B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma.

Kryczek I, Zou L, Rodriguez P, Zhu G, Wei S, Mottram P, Brumlik M, Cheng P, Curiel T, Myers L, Lackner A, Alvarez X, Ochoa A, Chen L, Zou W.

J Exp Med. 2006 Apr 17;203(4):871-81. Epub 2006 Apr 10.

12.

Restoring function in exhausted CD8 T cells during chronic viral infection.

Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, Freeman GJ, Ahmed R.

Nature. 2006 Feb 9;439(7077):682-7. Epub 2005 Dec 28.

PMID:
16382236
13.

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.

Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, Kepner J, Odunsi T, Ritter G, Lele S, Chen YT, Ohtani H, Old LJ, Odunsi K.

Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43. Epub 2005 Dec 12.

14.
15.

The B7 family revisited.

Greenwald RJ, Freeman GJ, Sharpe AH.

Annu Rev Immunol. 2005;23:515-48. Review.

PMID:
15771580
16.

The immunobiology of cancer immunosurveillance and immunoediting.

Dunn GP, Old LJ, Schreiber RD.

Immunity. 2004 Aug;21(2):137-48. Review.

17.

Lymphocyte activation gene-3 (CD223) regulates the size of the expanding T cell population following antigen activation in vivo.

Workman CJ, Cauley LS, Kim IJ, Blackman MA, Woodland DL, Vignali DA.

J Immunol. 2004 May 1;172(9):5450-5.

18.

Control of T cell viability.

Marrack P, Kappler J.

Annu Rev Immunol. 2004;22:765-87. Review.

PMID:
15032596
19.

Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells.

Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R.

Nat Immunol. 2003 Dec;4(12):1191-8. Epub 2003 Nov 16.

PMID:
14625547
20.

NY-ESO-1 and LAGE-1 cancer-testis antigens are potential targets for immunotherapy in epithelial ovarian cancer.

Odunsi K, Jungbluth AA, Stockert E, Qian F, Gnjatic S, Tammela J, Intengan M, Beck A, Keitz B, Santiago D, Williamson B, Scanlan MJ, Ritter G, Chen YT, Driscoll D, Sood A, Lele S, Old LJ.

Cancer Res. 2003 Sep 15;63(18):6076-83.

Supplemental Content

Support Center